Gish Biomedical's Titanium VasPort cleared:
This article was originally published in Clinica
Executive Summary
Gish Biomedical expects to add to its line of Hemed vascular access products later this year with its Titanium VasPort device following US FDA clearance last week. The new device, which will be rolled out at the American College of Surgeons meeting this week, will compete in a market worth $75 million. Gish is awaiting FDA clearance for its Hemed Dual Lumen VasPort implantable port device.